From Barchart: 2024-11-13 19:04:50

In Q3, Mersana Therapeutics exceeded revenue expectations, reporting approximately $12.6 million in earnings. Despite a loss of $0.09 per share, the company outperformed estimates. Financial metrics show a strong current ratio of 2.35, but challenges remain with negative cash flow and profitability ratios. Investors are optimistic about Mersana’s potential in the cancer treatment market, with a focus on developing antibody-drug conjugates.



Read more at Barchart:: Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 Earnin…